Celesta Capital
Featured
Prellis Biologics Secures $14.5M for Bioprinted Lymph Node
Prellis Biologics secured a $14.5 million series B round lead by Celesta Capital with existing shareholders Khosla Ventures. Prellis has an Externalized Immune System (EXIS) platform which allows researchers to discover…